Advertisement

Neurotherapeutics

, Volume 6, Issue 1, pp 14–27 | Cite as

Multifunctional drug treatment in neurotrauma

  • Bogdan Stoica
  • Kimberly Byrnes
  • Alan I. Faden
Review Article

Summary

Although the concepts of secondary injury and neuroprotection after neurotrauma are experimentally well supported, clinical trials of neuroprotective agents in traumatic brain injury or spinal cord injury have been disappointing. Most strategies to date have used drugs directed toward a single pathophysiological mechanism that contributes to early necrotic cell death. Given these failures, recent research has increasingly focused on multifunctional (i.e., multipotential, pluripotential) agents that target multiple injury mechanisms, particularly those that occur later after the insult. Here we review two such approaches that show particular promise in experimental neurotrauma: cell cycle inhibitors and small cyclized peptides. Both show extended therapeutic windows for treatment and appear to share at least one important target.

Key Words

Neurotrauma neuroprotection treatment cell cycle inhibitors small cyclized peptides 

References

  1. 1.
    Yakovlev AG, Faden AI. Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies. NeuroRX 2004;1:5–16.CrossRefPubMedGoogle Scholar
  2. 2.
    Faden AI, Stoica B. Neuroprotection: challenges and opportunities. Arch Neurol 2007;64:794–800.CrossRefPubMedGoogle Scholar
  3. 3.
    Faden AI. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition. Curr Opin Neurol 2002;15:707–712.CrossRefPubMedGoogle Scholar
  4. 4.
    Dumont RJ, Okonkwo DO, Verma S, et al. Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol 2001;24:254–264.CrossRefPubMedGoogle Scholar
  5. 5.
    Tator CH. Experimental and clinical studies of the pathophysiology and management of acute spinal cord injury. J Spinal Cord Med 1996;19:206–214.PubMedGoogle Scholar
  6. 6.
    Olney JW. Excitotoxin-mediated neuron death in youth and old age. Prog Brain Res 1990;86:37–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Faden AI. Comparison of single and combination drug treatment strategies in experimental brain trauma. J Neurotrauma 1993;10:91–100.CrossRefPubMedGoogle Scholar
  8. 8.
    Faden AI, Jacobs TP, Holaday JW. Thyrotropin-releasing hormone improves neurologic recovery after spinal trauma in cats. N Engl J Med 1981;305:1063–1067.CrossRefPubMedGoogle Scholar
  9. 9.
    Faden AI, Jacobs TP, Smith MT. Thyrotropin-releasing hormone in experimental spinal injury: dose response and late treatment. Neurology 1984;34:1280–1284.PubMedGoogle Scholar
  10. 10.
    Faden AI, Yum SW, Lemke M, Vink R. Effects of TRH-analog treatment on tissue cations, phospholipids and energy metabolism after spinal cord injury. J Pharmacol Exp Ther 1990;255:608–614.PubMedGoogle Scholar
  11. 11.
    Lux WE, Jr., Feuerstein G, Faden AI. Alteration of leukotriene D4 hypotension by thyrotropin releasing hormone. Nature 1983;302:822–824.CrossRefPubMedGoogle Scholar
  12. 12.
    Feuerstein G, Lux WE, Ezra D, Hayes EC, Snyder F, Faden AI. Thyrotropin-releasing hormone blocks the hypotensive effects of platelet-activating factor in the unanesthetized guinea pig. J Cardiovasc Pharmacol 1985;7:335–340.CrossRefPubMedGoogle Scholar
  13. 13.
    McIntosh TK, Vink R, Faden AI. An analogue of thyrotropin-releasing hormone improves outcome after brain injury: 31P-NMR studies. Am J Physiol 1988;254:R785–792.PubMedGoogle Scholar
  14. 14.
    McIntosh TK, Vink R, Faden AI. Beneficial effect of the TRH analog CG-3703 on outcome and survival following traumatic brain injury in rats. Prog Clin Biol Res 1988;264:415–420.PubMedGoogle Scholar
  15. 15.
    Faden AI. TRH analog YM-14673 improves outcome following traumatic brain and spinal cord injury in rats: dose-response studies. Brain Res 1989;486:228–235.CrossRefPubMedGoogle Scholar
  16. 16.
    Faden AI, Fox GB, Fan L, et al. Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents. Am J Physiol 1999;277:R1196–1204.PubMedGoogle Scholar
  17. 17.
    Faden AI, Sacksen I, Noble LJ. Structure-activity relationships of TRH analogs in rat spinal cord injury. Brain Res 1988;448:287–293.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang GL, Zhu C. Effects of thyrotropin-releasing hormone on acute experimental traumatic head injury in cats. Chin Med J (Engl) 1991;104:939–944.Google Scholar
  19. 19.
    Tanaka K, Ogawa N, Asanuma M, Kondo Y. Thyrotropin releasing hormone prevents abnormalities of cortical acetylcholine and monoamines in mice following head injury. Regul Pept 1997;70:173–178.CrossRefPubMedGoogle Scholar
  20. 20.
    Arias MJ. Treatment of experimental spinal cord injury with TRH, naloxone, and dexamethasone. Surg Neurol 1987;28: 335–338.CrossRefPubMedGoogle Scholar
  21. 21.
    Behrmann DL, Bresnahan JC, Beattie MS. Modeling of acute spinal cord injury in the rat: neuroprotection and enhanced recovery with methylprednisolone, U-74006F and YM-14673. Exp Neurol 1994;126:61–75.CrossRefPubMedGoogle Scholar
  22. 22.
    Puniak MA, Freeman GM, Agresta CA, Van Newkirk L, Barone CA, Salzman SK. Comparison of a serotonin antagonist, opioid antagonist, and TRH analog for the acute treatment of experimental spinal trauma. J Neurotrauma 1991;8:193–203.CrossRefPubMedGoogle Scholar
  23. 23.
    Pitts LH, Ross A, Chase GA, Faden AI. Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries. J Neurotrauma 1995;12:235–243.CrossRefPubMedGoogle Scholar
  24. 24.
    Friedman TC, Wilk S. Delineation of a particulate thyrotropin-releasing hormone-degrading enzyme in rat brain by the use of specific inhibitors of prolyl endopeptidase and pyroglutamyl peptide hydrolase. J Neurochem 1986;46:1231–1239.CrossRefPubMedGoogle Scholar
  25. 25.
    Coggins PJ, McDermott JR, Snell CR, Gibson AM. Thyrotrophin releasing hormone degradation by rat synaptosomal peptidases: production of the metabolite His-Pro. Neuropeptides 1987;10:147–156.CrossRefPubMedGoogle Scholar
  26. 26.
    Faden Knoblach SM, Movsesyan VA, Lea PMt, Cernak I. Novel neuroprotective tripeptides and dipeptides. Ann N Y Acad Sci 2005;1053:472–481.CrossRefGoogle Scholar
  27. 27.
    Faden AI, Labroo VM, Cohen LA. Imidazole-substituted analogues of TRH limit behavioral deficits after experimental brain trauma. J Neurotrauma 1993;10:101–108.CrossRefPubMedGoogle Scholar
  28. 28.
    Prasad C. Limited proteolysis and physiological regulation: an example from thyrotropin-releasing hormone metabolism. Thyroid 1998;8:969–975.CrossRefPubMedGoogle Scholar
  29. 29.
    Faden AI, Movsesyan VA, Knoblach SM, Ahmed F, Cernak I. Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacology 2005;49:410–424.CrossRefPubMedGoogle Scholar
  30. 30.
    Faden AI, Fox GB, Di X, et al. Neuroprotective and nootropic actions of a novel cyclized dipeptide after controlled cortical impact injury in mice. J Cereb Blood Flow Metab 2003;23:355–363.CrossRefPubMedGoogle Scholar
  31. 31.
    Faden AI, Knoblach SM, Cernak I, et al. Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo. J Cereb Blood Flow Metab 2003;23:342–354.CrossRefPubMedGoogle Scholar
  32. 32.
    Faden AI, Knoblach SM, Movsesyan VA, Cernak I. Novel small peptides with neuroprotective and nootropic properties. J Alzheimers Dis 2004;6:S93–97.PubMedGoogle Scholar
  33. 33.
    Cernak I, Stoica B, Byrnes KR, Di Giovanni S, Faden AI. Role of the cell cycle in the pathobiology of central nervous system trauma. Cell Cycle 2005;4:1286–1293.CrossRefPubMedGoogle Scholar
  34. 34.
    Byrnes KR, Stoica BA, Fricke S, Di Giovanni S, Faden AI. Cell cycle activation contributes to post-mitotic cell death and secondary damage after spinal cord injury. Brain 2007;130:2977–2992.CrossRefPubMedGoogle Scholar
  35. 35.
    Kitagawa M, Higashi H, Jung HK, et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. Embo J 1996;15:7060–7069.PubMedGoogle Scholar
  36. 36.
    Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. J Biol Chem 2002;277: 11617–11620.CrossRefPubMedGoogle Scholar
  37. 37.
    Di Giovanni S, Knoblach SM, Brandoli C, Aden SA, Hoffman EP, Faden AI. Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. Ann Neurol 2003;53:454–468.CrossRefPubMedGoogle Scholar
  38. 38.
    De Biase A, Knoblach SM, Di Giovanni S, et al. Gene expression profiling of experimental traumatic spinal cord injury as a function of distance from impact site and injury severity. Physiol Genomics 2005;22:368–381.CrossRefPubMedGoogle Scholar
  39. 39.
    Kangas A, Nicholson DW, Holtta E. Involvement of CPP32/ Caspase-3 in c-Myc-induced apoptosis. Oncogene 1998;16:387–398.CrossRefPubMedGoogle Scholar
  40. 40.
    Di Giovanni S, Movsesyan V, Ahmed F, et al. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci U S A 2005;102:8333–8338.CrossRefPubMedGoogle Scholar
  41. 41.
    Strazza M, Luddi A, Brogi A, et al. Activation of cell cycle regulatory proteins in the apoptosis of terminally differentiated oligodendrocytes. Neurochem Res 2004;29:923–931.CrossRefPubMedGoogle Scholar
  42. 42.
    Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS. Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F × DP, in B-amyloid-induced neuronal death. J Biol Chem 1999;274: 19011–19016.CrossRefPubMedGoogle Scholar
  43. 43.
    Padmanabhan J, Park DS, Greene LA, Shelanski ML. Role of cell cycle regulatory proteins in cerebellar granule neuron apoptosis. J Neurosci 1999;19:8747–8756.PubMedGoogle Scholar
  44. 44.
    Otsuka Y, Tanaka T, Uchida D, et al. Roles of cyclin-dependent kinase 4 and p53 in neuronal cell death induced by doxorubicin on cerebellar granule neurons in mouse. Neurosci Lett 2004;365:180–185.CrossRefPubMedGoogle Scholar
  45. 45.
    Kruman II, Wersto RP, Cardozo-Pelaez F, et al. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 2004;41:549–561.CrossRefPubMedGoogle Scholar
  46. 46.
    Park DS, Morris EJ, Bremner R, et al. Involvement of retinoblastoma family members and E2F/DP complexes in the death of neurons evoked by DNA damage. J Neurosci 2000;20:3104–3114.PubMedGoogle Scholar
  47. 47.
    Park DS, Obeidat A, Giovanni A, Greene LA. Cell cycle regulators in neuronal death evoked by excitotoxic stress: implications for neurodegeneration and its treatment. Neurobiol Aging 2000;21:771–781.CrossRefPubMedGoogle Scholar
  48. 48.
    Park DS, Levine B, Ferrari G, Greene LA. Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J Neurosci 1997;17:8975–8983.PubMedGoogle Scholar
  49. 49.
    Wiessner C, Brink I, Lorenz P, Neumann-Haefelin T, Vogel P, Yamashita K. Cyclin D1 messenger RNA is induced in microglia rather than neurons following transient forebrain ischaemia. Neuroscience 1996;72: 947–958.CrossRefPubMedGoogle Scholar
  50. 50.
    Kato H, Takahashi A, Itoyama Y. Cell cycle protein expression in proliferating microglia and astrocytes following transient global cerebral ischemia in the rat. Brain Res Bull 2003;60:215–221.CrossRefPubMedGoogle Scholar
  51. 51.
    Shen A, Liu Y, Zhao J, et al. Temporal-spatial expressions of p27kip1 and its phosphorylation on Serine-10 after acute spinal cord injury in adult rat: implications for post-traumatic glial proliferation. Neurochem Int 2008;52: 1266–1275.CrossRefPubMedGoogle Scholar
  52. 52.
    Tanaka T, Tatsuno I, Noguchi Y, et al. Activation of cyclin-dependent kinase 2 (Cdk2) in growth-stimulated rat astrocytes. Geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E gene expression. J Biol Chem 1998;273:26772–26778.CrossRefPubMedGoogle Scholar
  53. 53.
    Lee SC, Liu W, Brosnan CF, Dickson DW. GM-CSF promotes proliferation of human fetal and adult microglia in primary cultures. Glia 1994;12:309–318.CrossRefPubMedGoogle Scholar
  54. 54.
    Hoke A, Silver J. Heterogeneity among astrocytes in reactive gliosis. Perspect Dev Neurobiol 1994;2: 269–274.PubMedGoogle Scholar
  55. 55.
    Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci 2004;5:146–156.CrossRefPubMedGoogle Scholar
  56. 56.
    Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 1997;20:570–577.CrossRefPubMedGoogle Scholar
  57. 57.
    Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 2004;24:2143–2155.CrossRefPubMedGoogle Scholar
  58. 58.
    Raivich G, Jones LL, Werner A, Bluthmann H, Doetschmann T, Kreutzberg GW. Molecular signals for glial activation: pro- and anti-inflammatory cytokines in the injured brain. Acta Neurochir Suppl 1999;73: 21–30.PubMedGoogle Scholar
  59. 59.
    Benveniste EN. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol 1992;263:C1–16.PubMedGoogle Scholar
  60. 60.
    Lynch NJ, Willis CL, Nolan CC, et al. Microglial activation and increased synthesis of complement component C1q precedes blood-brain barrier dysfunction in rats. Mol Immunol 2004;40:709–716.CrossRefPubMedGoogle Scholar
  61. 61.
    Pawate S, Shen Q, Fan F, Bhat NR. Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J Neurosci Res 2004;77:540–551.CrossRefPubMedGoogle Scholar
  62. 62.
    Wharton SB, Williams GH, Stoeber K, et al. Expression of Ki67, PCNA and the chromosome replication licensing protein Mcm2 in glial cells of the ageing human hippocampus increases with the burden of Alzheimer-type pathology. Neurosci Lett 2005;383:33–38.CrossRefPubMedGoogle Scholar
  63. 63.
    Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease. J Neurosci 2003;23:2557–2563.PubMedGoogle Scholar
  64. 64.
    Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer’s disease. J Neurosci 2001;21:2661–2668.PubMedGoogle Scholar
  65. 65.
    Gartner U, Bruckner MK, Krug S, Schmetsdorf S, Staufenbiel M, Arendt T. Amyloid deposition in APP23 mice is associated with the expression of cyclins in astrocytes but not in neurons. Acta Neuropathol 2003;106:535–544.CrossRefPubMedGoogle Scholar
  66. 66.
    Newcomb EW. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 2004;15: 411–419.CrossRefPubMedGoogle Scholar
  67. 67.
    Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 2003;36:417–425.CrossRefPubMedGoogle Scholar
  68. 68.
    Dai Y, Grant S. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents. Curr Oncol Rep 2004;6:123–130.CrossRefPubMedGoogle Scholar
  69. 69.
    Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004;5:27–36.CrossRefPubMedGoogle Scholar
  70. 70.
    Abraham RT, Acquarone M, Andersen A, et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell 1995;83:105–120.CrossRefPubMedGoogle Scholar
  71. 71.
    Bossenmeyer-Pourie C, Chihab R, Schroeder H, Daval JL. Transient hypoxia may lead to neuronal proliferation in the developing mammalian brain: from apoptosis to cell cycle completion. Neuroscience 1999;91:221–231.CrossRefPubMedGoogle Scholar
  72. 72.
    Jorda EG, Verdaguer E, Canudas AM, et al. Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis. Neuropharmacology 2003;45:672–683.CrossRefPubMedGoogle Scholar
  73. 73.
    Verdaguer E, Jimenez A, Canudas AM, et al. Inhibition of cell cycle pathway by flavopiridol promotes survival of cerebellar granule cells after an excitotoxic treatment. J Pharmacol Exp Ther 2004;308:609–616.CrossRefPubMedGoogle Scholar
  74. 74.
    Hilton GD, Stoica BA, Byrnes KR, Faden AI. Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma. J Cereb Blood Flow Metab 2008;28:1845–1859.CrossRefPubMedGoogle Scholar
  75. 75.
    Tian DS, Yu ZY, Xie MJ, Bu BT, Witte OW, Wang W. Suppression of astroglial scar formation and enhanced axonal regeneration associated with functional recovery in a spinal cord injury rat model by the cell cycle inhibitor olomoucine. J Neurosci Res 2006;84:1053–1063.CrossRefPubMedGoogle Scholar
  76. 76.
    Tian DS, Dong Q, Pan DJ, et al. Attenuation of astrogliosis by suppressing of microglial proliferation with the cell cycle inhibitor olomoucine in rat spinal cord injury model. Brain Res 2007;1154:206–214.CrossRefPubMedGoogle Scholar
  77. 77.
    Rashidian J, Iyirhiaro G, Aleyasin H, et al. Multiple cyclin-dependent kinases signals are critical mediators of ischemia/hypoxic neuronal death in vitro and in vivo. Proc Natl Acad Sci U S A 2005;102:14080–14085.CrossRefPubMedGoogle Scholar
  78. 78.
    Wang F, Corbett D, Osuga H, et al. Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat. J Cereb Blood Flow Metab 2002;22:171–182.CrossRefPubMedGoogle Scholar
  79. 79.
    Osuga H, Osuga S, Wang F, et al. Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci U S A 2000;97:10254–10259.CrossRefPubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2009

Authors and Affiliations

  • Bogdan Stoica
    • 1
  • Kimberly Byrnes
    • 1
  • Alan I. Faden
    • 1
  1. 1.Department of NeuroscienceGeorgetown University School of MedicineWashington, DC

Personalised recommendations